DNAH11

Across TCGA pan-cancer cohorts, DNAH11 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated DNAH11 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher DNAH11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DNAH11 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

ACC, BLCA, and UCEC are the cancer types where DNAH11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.209	0.810	<.001	33	view →
BLCA	DFS	Median	All	0.610	0.314	.004	26	view →
UCEC	OS	Median	II,III,IV	0.856	0.313	.017	22	view →
READ	OS	Median	IV	0.289	0.899	<.001	8	view →
PRAD	DFS	Median	All	0.788	0.934	.005	6	view →
LIHC	DFS	Median	III,IV	0.079	0.333	.009	6	view →
LUAD	OS	Median	II,III,IV	0.495	0.699	.010	6	view →
SARC	DFS	Median	All	0.168	0.602	.001	4	view →
CHOL	DFS	Median	All	0.093	0.434	.046	3	view →
SKCM	OS	Median	IV	0.250	0.669	.013	3	view →
LGG	OS	Median	All	0.634	0.898	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

DNAH11–ACC (OS)

Open the ACC breakdown →